Key Highlights

  • OraSure shares were down 8.63 percent to USD 3.60 in pre-market trading on November 2, 2026.
  • On November 2, 2026, the company said it joined the World Coalition on Sickle Cell Disease.
  • The company will report third quarter 2026 results and host a call on November 9, 2026.
  • Second quarter 2026 Revenue was USD 30.6 million, down 2 percent year over year.
  • Cash and cash equivalents stood at USD 160.6 million on June 30, 2026.

What moved OraSure shares in pre-market trading?

OraSure Technologies (NASDAQ:OSUR) was down 8.63 percent to USD 3.60 in pre-market trading on November 2, 2026. Because the price is under USD 5, the stock is a Penny Stock by the common definition, and moves of this size can happen on thin early-session volume.

No company announcement that explains a decline was identified. The only item dated November 2, 2026 was a press release about a membership, which is not the kind of news that normally pressures a share price.

What did the company announce on November 2, 2026?

According to a company press release dated November 2, 2026, OraSure joined the World Coalition on Sickle Cell Disease, an international public-private Partnership focused on the global response to the condition. The company said it will contribute a diagnostics manufacturer's view drawn from its work in decentralized and point-of-care testing.

In a separate release dated October 27, 2026, the company said it will announce third quarter 2026 financial results and host an Earnings Call on November 9, 2026.

What does OraSure do and how did it perform recently?

OraSure is a global provider of point-of-care and home diagnostic tests and sample management solutions. Its subsidiaries include DNA Genotek, Sherlock Biosciences and BioMedomics, and it sells to laboratories, hospitals, public health bodies, governments, pharmaceutical companies and consumers.

In its second quarter 2026 results released on August 5, 2026, the company reported revenue of USD 30.6 million, down 2 percent from a year earlier. Diagnostics revenue rose 1 percent to USD 19.4 million. GAAP Net Income was USD 6.2 million, helped by a USD 22.6 million reduction in acquisition-related contingent consideration, while the non-GAAP net loss was USD 13.8 million.

GAAP gross Margin improved to 43.5 percent from 42.1 percent.

What are the risks and what should investors watch next?

The company said it withdrew its current InteliQuick CT/NG submission and plans a future submission, a regulatory item that may affect timing. Cash and cash equivalents were USD 160.6 million on June 30, 2026.

For the third quarter, the company guided to total revenue of USD 29.5 million to USD 32.5 million. The November 9, 2026 results will show where actual revenue landed within that range, along with cash and margin trends. Penny stocks can be volatile and less liquid, so price swings may be wide.